Verastem Reports Two-Year RAMP 201 Data in LGSOC
BOSTON — September 28, 2026 Verastem Oncology announced the publication in Gynecologic Oncology of two-year follow-up data from the...
KRAS
Advertisement
HUTCHMED Initiates Global Phase I Trial of HMPL-A830
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026 HUTCHMED (China) Limited announced the initiation of the...
Verastem to Present RAMP 201 Biomarker Data at IGCS 2026
BOSTON — September 24, 2026 Verastem Oncology announced that molecular profiling and tumor biomarker findings from the Phase 2...
Kestrel Therapeutics Gains FDA Fast Track for KST-6051
WATERTOWN, Mass. — September 15, 2026 Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE
REDWOOD CITY, Calif. — September 14, 2026 Revolution Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Advertisements
SELLAS Presents SLS009 Preclinical Data in Pancreatic Cancer at AACR 2026
New York, September 2, 2026 SELLAS Life Sciences Group, Inc. announced that three abstracts evaluating SLS009 (tambiciclib), a potent...
Akari Therapeutics and Whitehawk Expand Dual-Payload ADC Strategy
Tampa, Florida and London, United Kingdom — August 13, 2026 Akari Therapeutics, Plc reported progress on its lead antibody-drug...
BeOne Medicines Partners with Revolution Medicines on RAS Cancer Therapies
San Carlos, Calif. & Redwood City, Calif., August 10, 2026 BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a...
Firefly Bio Acquisition Strengthens J&J Cancer Portfolio
MONTEREY, Calif., July 29, 2026 Johnson & Johnson has completed its $1 billion acquisition of Firefly Bio, Inc., significantly...
IDEAYA Biosciences Advances IDE892 in MTAP-Deleted Cancers
SOUTH SAN FRANCISCO, Calif., July 27, 2026 IDEAYA Biosciences announced the initiation of Part 2 monotherapy expansion in its...
Advertisement
